Abstract
Events that contribute to tumor formation include mutations in the ras gene and loss or inactivation of cell cycle inhibitors such as p21Cip1 and p27Kip1. In our previous publication, we showed that mice expressing the MMTV/v-Ha-ras transgene developed tumors earlier and at higher multiplicities in the absence than in the presence of p21Cip1. To further evaluate the combinatorial role of genetic alterations and loss of cell cycle inhibitors in tumorigenesis, we performed two companion studies. In the first study, wild type and p21Cip1-null mice were exposed to the chemical carcinogen, urethane. Similar to its effects in v-Ha-ras mice, loss of p21Cip1 accelerated tumor onset and increased tumor multiplicity in urethane-treated mice. Lung tumors were the predominant tumor type in urethane-treated mice regardless of p21Cip1 status. In the second study, tumor formation was monitored in v-Ha-ras mice expressing or lacking p27Kip1. Unlike p21Cip1, the absence of p27Kip1 had no effect on the timing or multiplicity of tumor formation, which was largely restricted to mammary and salivary glands. However, once tumors appeared, they grew faster in p27Kip1-null mice than in p27Kip1-wild type mice. Increases in growth rate were particularly striking for salivary tumors in ras/p27−/− mice. Loss of p21Cip1, on the other hand, had no effect on tumor growth rate in v-Ha-ras mice. Collectively, our data suggest that p21Cip1 suppresses tumor formation elicited by multiple agents and that p21Cip1 and p27Kip1 suppress tumor formation in different ways.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adams JM, Cory S . 1991 Science 254: 1161–1167
Adnane J, Jackson RJ, Nicosia SV, Cantor AB, Pledger WJ, Sebti SM . 2000 Oncogene 19: 5338–5347
Agrawal D, Hauser P, McPherson F, Dong F, Garcia A, Pledger WJ . 1996 Mol. Cell. Biol. 16: 4327–4336
Aktas H, Cai H, Cooper GM . 1997 Mol. Cell. Biol. 17: 3850–3857
Andres AC, van der Valk MA, Schonenberger CA, Fluckiger F, LeMeur M, Gerlinger P, Groner B . 1988 Genes Dev. 2: 1486–1495
Bagui TK, Jackson RJ, Agrawal D, Pledger WJ . 2000 Mol. Cell. Biol. 20: 8748–8757
Bos JL . 1989 Cancer Res. 49: 4682–4689
Brugarolas J, Bronson RT, Jacks T . 1998 J. Cell Biol. 141: 503–514
Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, Hannon GJ . 1995 Nature 377: 552–557
Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI, Slingerland JM . 1997 Nat. Med. 3: 227–320
Davis RW, Thomas M, Cameron J, St John TP, Scherer S, Padgett RA . 1980 Methods Enzymol. 65: 404–411
Della Ragione F, Borriello A, Della Pietra V, Cucciolla V, Oliva A, Barbarisi A, Iolascon A, Zappia V . 1999 Adv. Exp. Med. Biol. 472: 73–88
Deng C, Zhang P, Harper JW, Elledge SJ, Leder P . 1995 Cell 82: 675–684
Di Cunto F, Topley G, Calautti E, Hsiao J, Ong L, Seth PK, Dotto GP . 1998 Science 280: 1069–1072
Dragani TA, Manenti G, Colombo BM, Falvella FS, Gariboldi M, Pierotti MA, Della Porta G . 1991 Oncogene 6: 333–338
Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ . 1998 Nature 396: 177–180
Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM . 1996 Cell 85: 733–744
Firpo EJ, Koff A, Solomon MJ, Roberts JM . 1994 Mol. Cell. Biol. 14: 4889–4901
Frame S, Balmain A . 2000 Curr. Opin. Genet. Dev. 10: 106–113
Hauser PJ, Agrawal D, Flanagan M, Pledger WJ . 1997 Cell Growth Differ. 8: 203–211
Johnson DG, Walker CL . 1999 Annu. Rev. Pharmacol. Toxicol. 39: 295–312
Jones JM, Cui XS, Medina D, Donehower LA . 1999 Cell Growth Differ. 10: 213–222
Joneson T, Bar-Sagi D . 1997 J. Mol. Med. 75: 587–593
Kawana H, Tamaru J, Tanaka T, Hirai A, Saito Y, Kitagawa M, Mikata A, Harigaya K, Kuriyama T . 1998 Am. J. Pathol. 153: 505–513
Kiyokawa H, Kineman RD, Manova-Todorova KO, Soares VC, Hoffman ES, Ono M, Khanam D, Hayday AC, Frohman LA, Koff A . 1996 Cell 85: 721–732
Kumar R, Sukumar S, Barbacid M . 1990 Science 248: 1101–1104
Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M . 1997 Nat. Med. 3: 231–234
Malkinson AM, Beer DS . 1983 J. Natl. Cancer Inst. 70: 931–936
Martin-Caballero J, Flores JM, Garcia-Palencia P, Serrano M . 2001 Cancer Res. 61: 6234–6238
Mirvish SS . 1968 Adv. Cancer Res. 11: 1–42
Missero C, Di Cunto F, Kiyokawa H, Koff A, Dotto GP . 1996 Genes Dev. 10: 3065–3075
Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY, Nakayama K . 1996 Cell 85: 707–720
Nuzum EO, Malkinson AM, Beer DG . 1990 Mol. Carcinog. 3: 287–295
Paramio JM, Segrelles C, Ruiz S, Martin-Caballero J, Page A, Martinez J, Serrano M, Jorcano JL . 2001 J. Biol. Chem. 276: 44203–44211
Philipp J, Vo K, Gurley KE, Seidel K, Kemp CJ . 1999 Oncogene 18: 4689–4698
Ponce-Castaneda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague J et al . 1995 Cancer Res. 55: 1211–1214
Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ, Daling JR, Roberts JM . 1997 Nat. Med. 3: 222–225
Quaroni A, Tian JQ, Seth P, Ap Rhys C . 2000 Am. J. Physiol. 279: C1045–C1057
Sandgren EP, Quaife CJ, Pinkert CA, Palmiter RD, Brinster RL . 1989 Oncogene 4: 715–724
Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW . 1997 Cell 88: 593–602
Sherr CJ, Roberts JM . 1995 Genes Dev. 9: 1149–1163
Shiohara M, Koike K, Komiyama A, Koeffler HP . 1997 Leuk. Lymphoma 26: 35–341
Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P . 1987 Cell 49: 465–475
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL . 1987 Science 235: 177–182
Smith GS, Walford RL, Mickey MR . 1973 J. Natl. Cancer Inst. 50: 1195–1213
Suda Y, Aizawa S, Hirai S, Inoue T, Furuta Y, Suzuki M, Hirohashi S, Ikawa Y . 1987 EMBO J. 6: 4055–4065
Takuwa N, Takuwa Y . 1997 Mol. Cell. Biol. 17: 5348–5358
Topley GI, Okuyama R, Gonzales JG, Conti C, Dotto GP . 1999 Proc. Natl. Acad. Sci. USA 96: 9089–9094
Vogelstein B, Kinzler KW . 1992 Cell 70: 523–526
Weinberg WC, Montano NE, Deng C . 1997 Oncogene 15: 685–690
Winston JT, Coats SR, Wang YZ, Pledger WJ . 1996 Oncogene 12: 127–134
Wiseman RW, Stowers SJ, Miller EC, Anderson MW, Miller JA . 1986 Proc. Natl. Acad. Sci. USA 83: 5825–5829
Yang WC, Mathew J, Velcich A, Edelmann W, Kucherlapati R, Lipkin M, Yang K, Augenlicht LH . 2001 Cancer Res. 61: 565–569
Zezula J, Casaccia-Bonnefil P, Ezhevsky SA, Osterhout DJ, Levine JM, Dowdy SF, Chao MV, Koff A . 2001 EMBO Rep. 2: 27–34
Zhou BP, Liao Y, Xia W, Spohn B, Lee MH, Hung MC . 2001 Nat. Cell. Biol. 3: 245–252
Zirbes TK, Baldus SE, Moenig SP, Nolden S, Kunze D, Shafizadeh ST, Schneider PM, Thiele J, Hoelscher AH, Dienes HP . 2000 Int. J. Cancer 89: 14–18
Acknowledgements
This work was supported by the Cortner-Couch Endowed Chair for Cancer Research (WJ Pledger), NIH Grants CA78038 (SM Sebti and WJ Pledger), CA67360 (WJ Pledger), and CA67771 (SM Sebti), and ACS Grant PF-99-320-01-CNE (RJ Jackson). The authors thank Dr James Roberts and Dr Tyler Jacks for generously providing knockout mice, Nancy Olashaw for manuscript preparation, Sandra Livingston for assistance with immunocytochemistry, and Steve Enkemann for helpful discussions. We also acknowledge the helpful service of the Molecular Imaging Core Laboratory and the Animal Care Core at the Moffitt Cancer Center.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Jackson, R., Adnane, J., Coppola, D. et al. Loss of the cell cycle inhibitors p21Cip1 and p27Kip1 enhances tumorigenesis in knockout mouse models. Oncogene 21, 8486–8497 (2002). https://doi.org/10.1038/sj.onc.1205946
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205946
Keywords
This article is cited by
-
Inability to phosphorylate Y88 of p27Kip1 enforces reduced p27 protein levels and accelerates leukemia progression
Leukemia (2022)
-
DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression
Nature Communications (2017)
-
Combined loss of PUMA and p21 accelerates c-MYC-driven lymphoma development considerably less than loss of one allele of p53
Oncogene (2016)
-
RETRACTED ARTICLE: TLE3 represses colorectal cancer proliferation by inhibiting MAPK and AKT signaling pathways
Journal of Experimental & Clinical Cancer Research (2016)
-
The role of DNA damage responses in p53 biology
Archives of Toxicology (2015)